Anne-Charlotte Rivière

Anne-Charlotte Rivière is a partner in Goodwin’s Life Sciences and Technology groups. Anne-Charlotte focuses on transactions in the life sciences and technology sectors, acting for companies at all stages of development, as well as investors and management teams.

She guides these companies beyond their equity financing on all their strategic challenges including collaboration, mergers and acquisitions, public offerings and reorganization.

Anne-Charlotte also assists private equity funds in their leveraged buy-out (LBO) transactions in several sectors including the healthcare and other regulated sectors.

She is also regularly involved in secondary transactions.

Prior to joining Goodwin in 2021, Anne-Charlotte was a partner at Dechert and previously worked in other international law firms.

Anne-Charlotte’s recent representative transactions include advising:

Life Sciences

• AlgoTx, a French biotech company which develops an innovative topical treatment for chemotherapy-induced peripheral neuropathy, in its €19 million Series B financing 
• DNA Script, a Parisian manufacturer of synthetic DNA, in its €172 million Series C financing round
• Depixus, a French life science tools company, in its €30 million Series A financing round
• Kiro, the first AI-powered digital health platform for clinical biology in Europe, in its €14 million Series A financing round
• Mablink Bioscience, a biotechnology company that seeks to bring new and better treatment options to cancer patients with unmet needs, in its sale to Lilly & Co.
• Bpifrance in its investment in the $103 million Series C financing round of ImCheck Therapeutics, a biotech company that designs and develops a new generation of immunotherapeutic antibodies
• Cathay Health in its investment in the €51 million Series B financing round of Moon Surgical, a Paris-based, early-stage medical device company, developing a surgical robot for laparoscopy assistance
• Go Capital in the €1,8 million Series Seed of Loop Dee Science, a solution for the detection of pathogens in biological samples
• Sofinnova Partners, Intermediate Capital Group as lead investors as well as new investors Tekla and CTI Life Sciences, in the €130 million Series C Financing of Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and related diseases
• SpeedInvest in the €3 million Series Seed financing of Orakl Oncology, a science-based startup leveraging a collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer

Technology

• Ascendance Flight Technologies, a sustainable flight solutions provider, in its €21 million Series A fundraising
• CO2.AI, an artificial intelligence-driven platform that empowers businesses to monitor and reduce their carbon footprint effectively, in its $12 million Series Seed financing
• Devialet, a French High-end speaker manufacturer, in its €50 million financing round
• Innovafeed, a biotech company leader in the rearing of insects for animal feed, in its €250 million Series D financing round
• Vestack, a prop-tech company, in its €10 million Series A new financing round
• Alven Capital Partners and Raise Conseil in the €3 million Series Pre-Seed financing of Skarlett, a new company engaged in the conception and management of a platform of equity releases and insurance solutions dedicated to the people over 60 years old
• BOND Capital in its investment in the €250 million Series C financing round of Ankorstore, an ecosystem that enables independent brands and retailers to thrive
• Confidential investors in the €500 million Series A financing round of Mistral.AI, a French-based company developing an AI-powered data entry system for companies
• SpeedInvest and Daphni in the $25 million Series A financing of Flow48, a FinTech operating in the MENA region, which provides revenue-based financing services to small and medium companies as an alternative lending model

LBO

• ArchiMed, a European investment firm specialized in the healthcare industries, in its reinvestment in Polyplus Transfection, a developer of innovative and cost-effective technology used in gene and cell therapy, following the partial sale of the group to global private equity firm Warburg Pincus*
• Eurazeo PME, a subsidiary of Eurazeo specialized in backing medium-sized companies, in its acquisition of Péters Surgical, a French group that designs, produces and distributes single-use medical equipment for surgical procedures*
• Cathay Capital Private Equity, a leading private equity firm dedicated to cross-border investment in Europe, China, and North America, in its investment in Cenexi Group, a European industrial organization specialized in pharmaceutical development and the manufacture of high value-added sterile products*

Secondary Transactions

• Committed Advisors in various portfolio acquisitions*
• 17Capital in various portfolio acquisitions*

*Denotes experience prior to joining Goodwin.

Anne-Charlotte is consistently recognized as a leader in her field by International and French preeminent, peer-reviewed publications.

• Ranked in Band 3 in Private Equity: Venture Capital and in Pharma/Life Sciences (Corporate) in the last edition of the Chambers Europe guide
• Ranked as Next Generation Partner in Healthcare and Life Sciences and Private Equity: Venture/Growth Capital in the last edition of the Legal 500 EMEA guide
• Recommended in Venture Capital Law, Private Equity Law and Mergers and Acquisitions Law in the last edition of Best Lawyers France

As a successful woman professional, Anne-Charlotte is committed to promoting Women leadership both inside and outside of the firm. As such, she co-leads Goodwin’s Paris Women’s Initiative Committee and has been driving women-oriented mentoring sessions, client initiatives and networking opportunities.

Anne-Charlotte’s recent publications and speaking engagement include:

Publications

• Interview, “Silicon Valley Bank, 6 mois après : qu’est-ce qui a changé pour les startups?,” Maddyness, October 2023
• Author, “Entre optimisme et réalisme, un équilibre difficile à trouver pour les entrepreneurs,” Maddyness, August 2023
• Interview, “Fermeture de la Silicon Valley Bank : quel impact pour la France?,” Maddyness, March 2023
• Co-Author (with Julie Messerig), “Bridge, entre perte d’attractivité et nécessité,” Biotech Finance, February 2023
• Co-Author (with Louis Taslé d’Héliand), “Dual Track: un et un font trois,” Biotech Finance, January 2023
• Co-Author (with Céline Domenget-Morin), “Biotechs, medtechs: ce qui ne me tue pas me fortifie ?,” Les Echos, January 2023
• Co-Author (with Sarah Fleury), “Property Sciences, un marché en devenir,” Business Immo, February 2022
• Interview, “L’Europe renforce le contrôle des rachats des stratégiques BioTech,” Maddyness, April 2020
• Interview, “Biotechs : décryptage du nouveau régime de contrôle des investissements étrangers,” Le Point, November 2020

Speaking Engagements

• Panelist in the session, “Key Collaboration and Financing Issues during the Covid-19 Pandemic,” HealthTech Innovation Days, October 2020